Healthcare

Discover how our integrated approach to analysing world Healthcare markets gives you the insight you need to inform critical decisions.

Latest

Cross-Border Collaborations In Europe Pose Upside and Downside Risks For Drugmakers

The increasing trend for European countries to collaborate, with respect to medicine pricing and reimbursement, poses risks to multinational pharmaceutical firms. While drugmakers are likely to benefit from greater market access through more streamlined pricing and reimbursement mechanisms, these agreements also pose significant risks to repressed medicine prices. We note that these agreements will be concentrated in smaller and less affluent markets across Europe; the major European powerhouses prefer to maintain autonomy in pricing negotiations.

Views

Reports

Analysts

Craig Smith

Pharmaceuticals & Healthcare Analyst
Pharmaceuticals & Healthcare | London

Peter Elphick

Pharmaceuticals & Healthcare Analyst
Pharmaceuticals & Healthcare | London

Kaushal Shah

Head of Pharmaceuticals and Healthcare Research
Pharmaceuticals & Healthcare | London

Jamie Davies

Head of Pharmaceuticals, Medical Devices and Healthcare Research
Pharmaceuticals & Healthcare | London
×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.